

**First data collection on the use of prophylactic migraine treatments including the monoclonal antibody Erenumab focused on the patient's personal experience**

Gaul C.<sup>1</sup>, Israel-Willner H.<sup>2</sup>, Schuh K<sup>3</sup>, Koch M.<sup>3</sup>

<sup>1</sup>Königstein, Germany; <sup>2</sup>Charité Berlin, Germany; <sup>3</sup>Novartis Pharma GmbH, Germany

**Background**

The perspective of patients regarding a new therapeutic option is not systematically captured. Quality of life including daily activity, time with the family and the wellbeing of the patient are deciding factors in migraine management. Thus, it is imperative to understand the patients' perspective on treatment with erenumab, a fully human monoclonal antibody targeting the CGRP receptor, available since November 2018 in Germany.

**Methods**

From July 2019 to December 2019, an online survey of German patients diagnosed with migraine collected details regarding their disease and experience with migraine therapies. Patients who had been on erenumab for at least three months were further asked about their treatment outcome and impact on their lives.

**Results**

An interim analysis covered 19740 migraine patients of which 39% had prior prophylactic treatment and 37% are using non-pharmaceutical treatments. The analysis included 91 erenumab patients with a mean of 18 years disease duration. These erenumab patients have tried 6.1 different pharmacologic prophylactic therapies on average. 85% of erenumab-patients stated that they can cope better with daily activities, 83% have fewer days lost to migraine since therapy initiation and 47% could already feel an improvement of their migraine symptoms after the first injection. For EAN congress, the full data set of >20,000 migraine patients will be presented.

**Conclusion**

PERISCOPE provides us the first real world data of German patients treated with erenumab and shows that patients' benefit from erenumab treatment with regard to improvement of quality of life and reduction of migraine specific symptoms.